PATENT CLAIM ANALYSIS

Application Number: 16109143
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["424", "489000"]

Abstract:
A granulation formulation of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide or pharmaceutically acceptable salt thereof, which is adapted for reconstitution with an aqueous vehicle, and associated oral suspension.

Claim (Index 1):
Direct blend powder for use in a pharmaceutical composition, comprising\n i) 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide hydrochloride, ii) 3.0 to 12.0 w/w % guar gum as a thickening agent, iii) 0.5 to 4.0 w/w % hypromellose as a suspending agent, iv) buffer, v) preservative, vi) anti-adherent or glidant, vii) sweetener, and viii) flavor.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 96.0
- Lexical Diversity: 1.14286
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14353141', '14994497', '13990515', '13989541', '13268387']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7061088789643267
- 35 USC 102 Novelty (BERT): 0.5818667550815506
- Combined Prediction Score: 0.6936846665760491
- Mean Citation Score: 335.881978
- Max Citation Score: 480.33377
- Similarity Product: 409.865444398008

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test